The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies.
Two cannabinoids receptors have been characterised in mammals; cannabinoid receptor type 1 (CBI) which is ubiquitous in the central nervous system (CNS), and cannabinoid receptor type 2 (CBII) that is expressed mainly in immune cells. Cannabinoids have been used in the treatment of nausea and emesis, anorexia and cachexia, tremor and pain associated with multiple sclerosis. These treatments are limited by the psychoactive side-effects of CBI activation. Recently CBII has been described within the CNS, both in microglia and neuronal progenitor cells (NPCs), but with few exceptions, not by neurons within the CNS. This has suggested that CBII agonists could have potential to treat various conditions without psycho-activity. This article reviews the potential for CBII agonists as treatments for neurological conditions, with a focus on microglia and NPCs as drug targets. We first discuss the role of microglia in the healthy brain, and then the role of microglia in chronic neuroinflammatory disorders, including Alzheimer's disease and Parkinson's disease, as well as in neuroinflammation following acute brain injury such as stroke and global hypoxia. As activation of CBII receptor on microglia results in suppression of the proliferation and activation of microglia, there is potential for the anti-inflammatory properties of CBII agonist to treat neuropathologies that involve heightened microglia activity. In addition, activating CBII receptors may result in an increase in proliferation and affect migration of NPCs. Therefore, it is possible that CBII agonists may assist in the treatment of neuropathologies by increasing neurogenesis. In the second part of the article, we review the state of development of CBII selective drugs with an emphasis on critical aspects of CBII agonist structural activity relationship (SAR).
Department of Pharmacology & Toxicology, University of Otago, Dunedin, New Zealand.
Jack Rocky-Jay
JR
Rivers
John Clive
JC
Ashton
D000818:Animals; D002186:Cannabinoids / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002490:Central Nervous System / Q000033:anatomy & histology / Q000473:pathology*; D003198:Computer Simulation; D003863:Depression / Q000473:pathology / Q000503:physiopathology; D004314:Down Syndrome / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D017628:Microglia / Q000502:physiology; D015394:Molecular Structure; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D055495:Neurogenesis / Q000187:drug effects; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists*
D002186:Cannabinoids; D043885:Receptor, Cannabinoid, CB2